Corcept Therapeutics Incorporated (HTD F) stock market data APIs
€67.5315
5.57(8.2%)
as of December 16, 2025
Try our APIs with
free plan!
Corcept Therapeutics Incorporated Financial Data Overview
Price chart is built with
Anychart
Corcept Therapeutics Incorporated engages in discovery and development of medication for the treatment of severe endocrinologic, oncologic, metabolic, and neurologic disorders in the United States. It offers Korlym tablets medication for the treatment of hyperglycemia secondary to hypercortisolism in adult patients with endogenous cushing's syndrome; and who have type 2 diabetes mellitus or glucose intolerance and have failed surgery or are not candidates for surgery. The company is also developing relacorilant, which is in phase III clinical trial for the treatment of hypercortisolism; relacorilant combined with nab-paclitaxel which is in phase III clinical trial to treat platinum-resistant ovarian tumors; treatment for adrenal cancer and cortisol excess which is in phase 1b clinical trial; and for treatment for prostate cancer which is in phase II clinical trial. In addition, it develops dazucorilant, which is in phase II clinical trial for the treatment of amyotrophic lateral sclerosis; and miricorilant, which is in phase IIb trial for the treatment of metabolic dysfunction-associated steatohepatitis. The company was incorporated in 1998 and is headquartered in Redwood City, California.
Prev. Close
67.5315
Open
73.0974
High
73.1305
Low
67.0688
52 wk Range
48.28-105.3
Market Cap
7 188 M
P/E Ratio
91.4324
Shares Outstanding
105 M
Revenue
741 M
EPS
0.21
Beta
0.195
* We provide hundreds of fields of fundamental data, including EBITDA, P/E ratio, PEG ratio, trailing P/E, shareholders, insider transactions, technical metrics, dividends, splits, earnings, and more. Check out our Fundamental Data API.
Why to choose EODHD?
Prices start at $19.99
24/7 Live support
Robust, powerful and reliable data
API Simplicity of a few lines of code
Try our APIs
with free plan!
Or get access to advanced financial data starting only $19.99
TRY NOW
Get Corcept Therapeutics Incorporated data using free add-ons & libraries
Get Corcept Therapeutics Incorporated Fundamental Data
Corcept Therapeutics Incorporated Fundamental data includes:
- Net Revenue: 741 M
- EBITDA: 66 713 K
- Earnings Per Share:
- Income Statements
- Balance Sheets
- Cash flows
Plans with Fundamental data
Starting from
$
59.99
/mo.
End-of-day & Earnings data
What’s included:
- Latest Release: 2021-07-29
- EPS/Forecast: 0.16
What’s included:
- End of Day, Intraday and Live APIs
- Splits
- Dividends
Corcept Therapeutics Incorporated News
New
3 Growth Companies With High Insider Ownership And 13% Revenue Growth
As the U.S. stock market experiences a pullback with major indices like the S&P 500 and Dow Jones facing consecutive losses, investors are increasingly cautious amid concerns over an AI bubble and tep...
Three Insider-Favored Growth Companies To Watch
As the U.S. stock market grapples with pressures on AI stocks and anticipates key economic data releases, investors are keenly observing how these factors influence broader market trends. In such a vo...
Corcept (CORT): Buy, Sell, or Hold Post Q3 Earnings?
Corcept has followed the market’s trajectory closely, rising in tandem with the S&P 500 over the past six months. The stock has climbed by 13.8% to $81.75 per share while the index has gained 13.9%....
Why Corcept (CORT) Stock Is Down Today
What Happened? Shares of biopharma company Corcept Therapeutics (NASDAQ:CORT) fell 9.2% in the afternoon session after investment bank UBS initiated coverage of the company with a Neutral rating. Th...
Try our APIs
with free plan!
Or get access to advanced financial data starting only $19.99
TRY NOW
- Flexibility: No long-term commitments, just a minimum of one month
- Instant access: Get your API key and instructions within seconds of subscribing
- Price stability: Locked-in rates for subscribed users, never changing
All-In-One
$99.99/mo.
What’s included:
- API Calls per Day: 100 000/day
- API Requests per Min.: 1000/minute
- Type of Usage: Personal use
Data access:
Historical EOD, Fundamental, Real-Time, Intraday, Live (Delayed), Technical & Screener APIs, News Feed, 40 000 Stock Logos and many more. See a full list.
